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Objectives: To compare patency and complication rates of polytetrafluoroethylene (PTFE) grafts and denatured homologous 
vein (DHV) grafts for long-term haemodialysis. 
Design: A prospective randomised multicentre trial. 
Materials: One hundred and thirty-one patients were enrolled between September 1994 and April 1997. Sixty-three 
DHV grafts and 68 PTFE grafts were implanted in 60 males and 71 females. Complications and interventions were 
monitored. Patency rates, complication rates, and intervention rates of PTFE and DHV were compared. 
Results: The mean follow-up was 313 days for DHV (range 1-77I) and 339 (3-909) days for PTFE. The total follow- 
up was 54.1 patient-years for DHV and 63.1 for PTFE. The 1-year primary patency rates were 30% and 40% for DHV 
and PTFE respectively. Secondary patency rate was 63% for both DHV and PTFE. Most frequent complication was 
thrombosis. A total of 75 thrombotic events (1.39 per patient-year) occurred in 35 (56%) DHV grafts and 78 (1.24 per 
py) in 36 (53%) PTFE grafts. A total of nine infections were seen in nine (14%) DHV grafts, whereas 21 infections in 
20 (29%) PTFE grafts were seen (p = 0.08). All but one infected DHV graft could be salvaged with systemic antibiotics. 
In contrast, surgical intervention was necessary in nine PTFE grafts (p =0.02). For aneurysms, eight DHV and two 
PTFE grafts needed revision (p = 0.03). 
Conclusion: Patency rates between DHV and PTFE were not different. More infections were seen in PTFE grafts, and 
significantly more PTFE grafts needed surgical revision or removal because of infection. Significantly more DHV grafts 
were surgically revised or removed because of aneurysms. 
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Introduction 
For the construction of a vascular access for haemo- 
dialysis, several biological and synthetic materials 
have been introduced. Polytetrafluoroethylene (PTFE), 
which was introduced by Baker in 1976, is now the 
most commonly used material for these so-called 
bridge grafts. 1The cumulative secondary patency rates 
of PTFE vary from 60-87% after 1 year and 43-69% 
after 3 years. 28 Beside stenosis and thrombosis, in- 
fection is a major cause of morbidity and even mortality 
in patients with PTFE grafts, with reported rates from 
8.5 up to 35%. 4"6'8-11 In 1969, May et al. were the first 
to describe the use of saphenous vein for the creation 
of a bridge graft. 12 The relative unavailability of the 
autologous aphenous vein has prompted the use of 
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fresh or preserved homologous vein grafts. 13'14 Later 
this led to industrially prepared and commercially 
available denatured homologous vein (DHV) grafts. 15 
In 1983 we started to use denatured homologous 
vein grafts for vascular access urgery in our hospital, 
and it became the material of first choice for this 
purpose. In a retrospective study we evaluated the 
use of 195 DHV grafts as conduit for haemodialysis 
access. 16 The primary and secondary patency rates 
were comparable with the results of PTFE in lit- 
erature. 17'18 In contrast o PTFE grafts, the infection 
rate in DHV grafts was very low (2.6%) and all infected 
grafts could be salvaged by bypassing the infected 
area, with no further complications. Because of the 
potential clinical relevance, this prospective study was 
undertaken to compare patency and complication rates 
of PTFE and DHV grafts for chronic haemodialysis 
in a prospective randomised trial. We hypothesised 
comparable patency rates but lower rate and limited 
extent of infection in DHV grafts compared to PTFE 
grafts. 
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Patients and Methods 
A prospective randomised multicentre trial was con- 
ducted between September 1994 and April 1997. One 
university hospital, six general hospitals and one unit 
for home dialysis participated in this study. 
Patients in whom a Brescia-Cimino fistula failed 
or could not be constructed and patients who had 
previously undergone secondary access urgery were 
eligible. The study was approved by the Ethics Com- 
mittee of the hospitals concerned, and informed con- 
sent was obtained from each patient. In each hospital 
the DHV grafts and the PTFE grafts were randomly 
assigned to the patients by means of tables of random 
numbers generated by computer. 
The denatured homologous vein grafts (Varivas®- 
Medicor, The Netherlands) were produced according 
to the method described by BonnaudJ 5 Saphenous 
vein stripped uring varicose vein surgery is collected 
in vials containing 0.01% chlorohexidine solution. 
After storage at 4 °C for at least 4 weeks in this solution, 
which destroys antigenicity, the preparation procedure 
is undertaken. For the production the best vein parts 
are selected. Quality selection criteria are: (1) regularity 
and length of the vein segment; (2) the size of the 
kmer vessel diameter from 5 to 8 ram; and (3) the 
macroscopic appearance of the vascular wall. Side 
branches are ligated using 5 x 0 prolene and, to acquire 
a useful ength of the prosthesis, horter segments are 
anastomosed with 6 x 0 prolene. A leakage test is 
performed using isotonic saline solution under 
200 mmHg pressure. Finally the prosthesis, maintained 
in position by a glass rod through the lumen, is 
inserted in a stoppered glass cylinder containing 0.02 g 
chloramphenicol per 100 ml isotonic saline solution. 
The PTFE graft was mostly (91%) a 6 mm graft, either 
standard PTFE (IMPRA® or Gore-tex®) or stretch- 
PTFE (Gore-tex®). 
Patient characteristics, the details of the construction, 
and the use of drugs were registered. Prospectively, 
complications and interventions were monitored in- 
cluding thrombotic events, and subsequent inter- 
vention, and elective interventions to prevent 
thrombosis. Infection was defined as evidence of local 
inflammation eeding systemic antibiotics and/or sur- 
gical intervention. Additionally, other complications 
requiring intervention including stenosis, aneurysm, 
steal syndrome, and bleeding, were recorded. An- 
eurysms were corrected surgically when they were 
clinically judged potentially harmful for the patient or 
for the graft function. For sample size calculations, we 
used the intervention rate per patient-year as the 
primary end-point. With at least 60 patients in both 
trial arms, we were able to estimate a difference of 0.4 
intervention per patient per year (~=0.05, [3 = 0.20). 
Patients were followed until definite failure of the 
graft, or otherwise to the end of the study period. 
Patency rates, complication rates, and intervention 
rates of PTFE and DHV were compared. The effect of 
diabetes mellitus, clinically apparent vascular disease 
(that is a history of myocardial infarction, angina 
pectoris, cerebral or peripheral vascular disease), age 
above 60 years (median age), on patency rates was 
evaluated. The relationship between patency rates and 
the site of graft creation and the number of previous 
grafts was also assessed. 
Data Analysis 
Primary patency rate was defined as the percentage 
of grafts that functioned well without any surgical 
or catheter intervention after implantationJ 9 Primary 
assisted patency was defined as the percentage of 
grafts that functioned well after surgical or catheter 
intervention to prevent graft failure. 2° Secondary pat- 
ency was defined as those remaining patent after 
elective intervention or intervention for graft failure. I9 
The incidence rate was defined as the number of 
complications or interventions per patient-year. 
Cumulative incidence was used for the calculation 
of patency rates with Kaplan-Mei,er analysis. Patients 
who died, who were lost to follow-up, who were 
transplanted, or who were withdrawn alive, were 
censored. Differences in the patency rates were tested 
with Log-rank test. The Cox proportional hazards 
survival analysis was used to assess the effect of risk 
factors on patency rates. Because complications could 
occur and recur within one patient, incidence rates 
per patient-year were calculated. Differences between 
incidence rates of complication were calculated with 
Poisson regression analysis. Around the estimates 95% 
confidence limits were calculated. A p value <0.05 was 
considered significant. 
Results 
One hundred and thirty-one patients were enrolled. 
Sixty-three DHV grafts and 68 PTFE grafts were im- 
planted in 60 males and 71 females. There were 108 
loop forearm grafts, 17 straight forearm grafts, three 
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Fig. 1. Life table: Primary cumulative patency of DHV and PTFE 
grafts. (DHV=denatured homologous vein, PTFE=polytetra- 
fluoroethylene). 
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Fig. 2. Life table: Primary assisted cumulative patency of DHV and 
PTFE grafts. (DHV=denatured homologous vein, PTFE=poly- 
tetrafluoroethylene). 
Table 1. Demographic data of included patients. 
DHV PTFE 
Total grafts 63 68 
Type of grafts 
Loop forearm 54 55 
Straight forearm 5 12 
Upper-arm 3 0 
Thigh 1 1 
Age (mean + S.D.) 60.2 + 12.2 59.3 ± 15.5 
Sex 
Male 24 37 
Female 39 31 
Medical history 
Cerebrovascular disease 8 8 
Coronary artery disease 20 14 
Peripheral vascular disease 12 14 
Diabetes mellitus 21 22 
Numbers indicate number of patients, unless indicated otherwise. 
None of the demographic characteristics showed a significant dif- 
ference between the groups. (DHV = denatured homologous vein, 
PTFE = polytetrafluoroethylene, py = patient year). 
loop upper arm grafts and two loop thigh grafts (Table 
1). Sixty-nine (53%) patients received a graft because 
of failure of their Brescia-Cimino fistula, 24 (18%) 
because of failure of their secondary access and in 38 
(29%) patients pr imary  creation of a Brescia-Cimino 
fistula was not possible. The mean fol low-up was 313 
days for DHV (range 1-771) and 339 (3-909) days for 
PTFE. The total fo l low-up was 54.1 patient-years for 
DHV and 63.1 patient-years for PTFE. Dur ing this 
s tudy 18 patients (29%) died, eight DHV (13%) and 
10 PTFE (15%). In both the DHV and PTFE groups 
three patients underwent a successful kidney trans- 
plantation. Primary patency was not statistically dif- 
ferent in the two groups. Cumulative patency at 6, 12 
and 18 months was 51%, 30% and 22%, respectively, 
for DHV and 52%, 40% and 28%, respectively, for 
PTFE. Primary assisted and secondary patency was 
also similar. At 6, 12 and 18 months primary assisted 
patency was 65%, 40% and 32%, respectively, for DHV, 
57%, 45% and 34%, respectively, for PTFE. Secondary 
patency was 80%, 63% and 54%, respectively, for DHV, 
71%, 63% and 63%, respectively, for PTFE. 
Only 15 (24%) DHV and 16 (24%) PTFE grafts func- 
tioned without any complications throughout he 
study period. The most frequent complication was 
thrombosis, a total of 75 thrombotic events (1.39 per 
patient-year (py)) occurred in 35 (56%) patients with 
a DHV graft and 78 (1.24 per py) in 36 (53%) patients 
with a PTFE graft (Table 2). When all the first episodes 
of thrombosis in every patient were analysed, the 
proportion of early thrombosis (within 24h) was 
8/35 (23%) for DHV and 4/36 (11%) for PTFE. After 
1 week this was 11/35 (31%) for DHV and for PTFE 
this was still 4 /36 (11%). The hazard ratio for throm- 
bosis was 0.87 (95% CI 0.55-1.40) for PTFE. Most of 
the thrombotic episodes could be salvaged by  either 
surgical or radiological intervention. However ,  21 
events in the DHV group (0.39 per patient-years) and 
17 (0.27 per py) in the PTFE group were beyond repair. 
Infection was the more frequent complicat ion in PTFE 
grafts. A total of nine infections were seen in nine 
(14%) patients with DHV, whereas 21 infections in 20 
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Table 2. Thrombosis and the therapy for thrombosis. 
DHV PTFE 
Total Patients Incidence Total Patients Incidence 
per py per py 
Thrombosis 75 35 1.39 78 36 1.24 
Thrombectomy 19 9 0.35 30 19 0.48 
Thrombectomy and revision 26 21 0.48 22 17 0.35 
Fibrinolysis 1 1 0.02 2 2 0.03 
Fibrinolysis and pta 8 7 0.15 7 6 0.11 
Failure beyond repair 21 21 0.39 17 17 0.27 
Number of events and number of patients are indicated. (DHV = denatured homologous vein, PTFE = polytetrafluoroethylene, 
py = patient year, pta = percutaneous transluminal ngioplasty). 
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Fig. 3. Life table: Secondary cumulative patency of DHV and PTFE 
grafts. (DHV=denatured homologous vein, PTFE=polytetra- 
fluoroethylene). 
(29%) PTFE grafts were seen (rate ratio: 2.0, 95% CI 
0.9-4.4, p = 0.08) (Table 3). Of the total of 30 episodes 
of infection, 14 occurred before first needling of the 
graft. In the DHV group all infections but one could be 
salvaged with systemic antibiotics. In contrast, surgical 
intervention was necessary in nine PTFE grafts (rate 
ratio: 11.1, 95% CI 1.5-85.2, p=0.02)  of wh ich  two 
could  be sa lvaged,  two were  excised after one or more  
operat ions,  and  five were  excised as pr imary  therapy.  
Two pat ients  d ied  f rom septic p rob lems subsequent  
to a graft infect ion (both grafts were  excised). 
The indicat ions for all intervent ions,  both  curat ive 
and  elective, per fo rmed to mainta in  graft  patency  are 
summar ised  in Table 4. The intervent ions  concern ing 
the imp lantat ion  of a new graft  because of fai lure 
beyond repair  are not  inc luded.  Beside the di f ference 
in intervent ion rate for infection, the di f ference in 
intervent ion rate for aneurysms was also signif icant. 
Aneurysms necess i tat ing surgical  rev is ion occurred 
more  f requent ly  in DHV grafts. Of five false and four 
true aneurysms,  seven were  sa lvaged by  excis ion or 
l igat ion of the invo lved  area and  two grafts were  
rep laced  by  a new graft. Two PTFE grafts w i th  false 
aneurysms were  sa lvaged by  surgical  rev is ion (rate 
ratio: 0.19, 95% CI 0.04-0.88, p=0.03) .  No  major  com- 
p l icat ions were  seen in grafts w i th  an aneurysm,  nei-  
ther before nor  after surgical  revis ion. Overal l ,  97 
intervent ions  (1.79 per  py)  were  per fo rmed in 48 DHV 
grafts and 101 (1.60 per  py)  in 52 PTFE grafts. A 
vascu lar  d isorder ,  d iabetes mel l i tus  or a h igher  age 
(older than 60 years)  d id  not  show a signif icant h igher  
re lat ive r isk for compl icat ions.  No  di f ference was  seen 
in the patency  or compl icat ion  rate of a pat ient 's  first 
versus  second or th i rd  graft. The secondary  patency  
Table 3. Infection and therapy for infection. 
DHV PTFE 
Total Patients Incidence Total Patients Incidence 
per py per py 
Infection 9 9 0.17 21 20 0.32* 
Antibiotics 8 8 0.15 12 12 0.19 
Surgical revisions 1 1 0.02 13 9 0.21"* 
Revision 1 1 0.00 2 2 0.03 
Revision, later excision 0 0 0.00 6 2 0.10 
Excision 0 0 0.00 5 5 0.08 
Number of events and number of patients are indicated. (DHV = denatured homologous vein, PTFE = polytetrafluoroethylene, 
py = patient year). * p = 0.08, ** p = 0.02. 
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Table 4. Indicat ions for interventions. 
DHV PTFE 
Total Patients Incidence Total Patients Incidence 
per py per py 
Thrombosis 54 28 1.00 61 29 0.97 
Infection 1 1 0.02 13 9 0.21" 
Haemorrhage/haematoma 6 5 0.11 4 1 0.06 
Aneurysm 9 8 0.17 2 2 0.03"* 
Steal syndrome 2 1 0.04 3 3 0.05 
Elective 24 12 0.44 17 14 0.27 
Surgical revision 7 5 0.13 3 3 0.05 
PTA 17 11 0.31 14 13 0.22 
Other causes 1 1 0.02 1 1 0.02 
Total 97 48 1.79 101 52 1.60 
Number  of events and number  of patients are indicated. (DHV = denatured homologous vein, PTFE = polytetrafluoroethylene). 
* p =0.02, ** p = 0.03. 
was significantly worse in straight forearm grafts, 
compared to the looped forearm grafts (p = 0.01). The 
relative risk for a straight graft was 2.5 (95% CI 1.2-5.2). 
Discussion 
In this prospective randomised trial we found no 
differences in patency rates between DHV and PTFE 
grafts. Complication rates were comparable, except 
for the need for intervention for aneurysms, which 
occurred more frequently in DHV grafts, and the need 
for intervention for infection, which was seen more 
frequently and more extensively in PTFE grafts. This 
study clearly underscores the existing evidence that 
access related morbidity is extensive. 
In a period of approximately 2.5 years, 131 patients 
were enrolled in this multicentre study. We found a 
1-year secondary patency rate of 63% for DHV. This 
is somewhat lower than the 76% in our retrospective 
analysis, 16 but is comparable with the results of Gecim 
et al. 21 They reported a secondary patency of 66.4% in 
a prospective study of 36 DHV grafts. Bonnaud et al. 
described their 20 years' experience in secondary ac- 
cess surgery. They implanted 234 self-made and man- 
ufactured DHV grafts and 162 PTFE grafts. 22 These 
authors found a higher 1-year secondary patency rate 
for DHV (+83%) compared to our study, but they 
also found better results for PTFE grafts (+ 78% at 1 
year). 
The most frequent complication was thrombosis. In 
more than half of all patients at least one episode of 
thrombosis occurred within the study period. This 
resulted in incidence rates of 1.39 and 1.24 events per 
patient-year, despite of 0.44 and 0.29 elective in- 
terventions per patient-year meant o prevent hrom- 
bosis, for DHV and PTFE, respectively. Compared 
with literature data the rates of thrombosis are higher 
than reported by Besarab et aL 23 and Schwab et aI., 24 
but comparable to the results of Beathard. 25 Of note is 
the finding of a higher thrombosis rate within the first 
week of construction i DHV grafts compared to PTFE 
graft. Conceivably this might have been caused by 
the higher risk of twisting the DHV graft during 
implantation. 
The difference in the overall infection rate of DHV 
and PTFE was not significant. However, the number of 
cases in which surgical intervention for these infections 
was done was significant(p =0.02). In the DHV group 
only one patient needed surgical intervention, and the 
graft was salvaged. This finding is comparable with 
the 2.6% infection needing surgical intervention in 
our retrospective analysis, 16 and with the 2% serious 
infections described by Bonnaud et a/. 22 In contrast, 
surgical intervention was necessary in nine PTFE 
grafts, of which only two could be salvaged. Several 
authors described good salvage results in PTFE grafts, 
using one- or two-stage segmental bypasses ,  4'11'26 
though others removed most of the infected grafts in 
their patients. 3'6'27'28 Two patients with a PTFE graft 
died after a graft infection. In both patients an effort 
was made to salvage the graft by surgical intervention, 
but eventually both grafts were excised. Ap- 
proximately half of all episodes of infection occurred 
before first needling of the graft, and therefore should 
be considered as per- or postoperative complications. 
The number of operation related infections is high in 
comparison with most of the literature, 4'29'3° although 
for PTFE graft insertion an incidence of infection as 
high as 15% has been described. 4 The standard anti- 
biotic protocol included a single dose of either cephalo- 
sporin or flucloxacillin, 30 min before the operation. 
However, not all patients received antibiotics prior to 
surgery. Eleven grafts, six DHV and five PTFE, were 
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implanted wi thout  prophylact ic  antibiotics prior to 
operation. However ,  in these DHV grafts only one 
infection occurred (after 87 days), and in the PTFE 
grafts also one infection occurred (after 145 days). 
Thus, a relation with the absence of prophylact ic  anti- 
biotics is unlikely. The use of prophylact ic  antibiotics 
has been shown to be valuable in prevent ing infection, 
though others have not been able to confirm this 
finding. 10,26,31 
We were not able to f ind a relationship between the 
use of drugs, such as aspirin and warfarin, and graft 
function, possibly because the number  of patients in 
this s tudy was too small. 32~4 Neither were we able to 
find a relationship between diabetes mellitus, clinically 
apparent  vascular disease, or age >60 years and graft 
function. The choice of the donor  artery for the con- 
struction of the graft did make a difference. Of all 
grafts, 92% were placed in the forearm, usual ly in a 
looped conf igurat ion (brachial artery) and in 17 cases 
as straight grafts (radial artery). The patency was 
significantly worse in these straight forearm grafts, 
compared to the looped forearm grafts. Better results 
for straight grafts compared to looped grafts have 
been described, 35 but most  authors have described 
worse results for straight grafts. 4'6'36 It is conceivable 
that the flow in a graft anastomosed with the radial 
artery is lower than in a graft anastomosed with the 
larger brachial artery. 37 Furthermore,  in our study, 
most  of the straight grafts were converted f rom Bres- 
c ia-Cimino fistulas and not initially created as a sec- 
ondary  access. In most  of these straight grafts the 
anastomosis was created with an arterialised vein in 
the wrist and therefore the graft has in fact a third 
anastomosis,  which also may affect graft flow. Both 
factors may influence the patency of straight grafts, 
since it has been shown that a low graft f low increases 
the risk for graft thrombosis.  3°'3s'39 
In conclusion, it is clear that none of the available 
graft materials offer opt imal  performance. Thrombosis  
and infection remain the main complications. Our  
study shows that infection occurs less frequently 
in DHV compared to PTFE, and that these infections 
are usual ly limited. However ,  intervention for aneur- 
ysms occurs more frequently in DHV grafts. Other- 
wise, the two materials do not show important  
differences. 
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Appendix 
The following centres participated in the Study of 
Graft Materials in Access Surgery for Haemodialysis 
(with numbers of patients randomised and principal 
investigators): Medisch centrum Alkmaar (7, H. A. 
van Dijk, J. A. van Geelen), Andreas Ziekenhuis Am- 
sterdam (12, R. Weller, J. G. Kromhout, J. R. Beukhof), 
Sint Lucas Ziekenhuis Amsterdam (8, A. Voorwinde, 
B. H. Potter van Loon), Medicentum Den Bosch (11, 
J. G. Olsman, J. L. J. Jansen, M. I. Koolen), Rode Kruis 
Ziekenhuis Den Haag (11, P. J. Breslau, R. M. Valentijn, 
Y. I. Tjandra), Westeinde Ziekenhuis Den Haag (22, 
Ch. Ulrich, A. P. C. van der Maas, J. B. Rosman), 
Academisch Ziekenhuis Utrecht and Stichting Thuis- 
dialyse Utrecht (60, B. C. Eikelboom, P. J. Blankestijn, 
P. F. Vos, J. Vos, M. P. Kooistra). 
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